Nabriva Therapeutics Past Earnings Performance
Past criteria checks 0/6
Nabriva Therapeutics has been growing earnings at an average annual rate of 14.9%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 39.3% per year.
Key information
14.9%
Earnings growth rate
53.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 39.3% |
| Return on equity | -1,736.6% |
| Net Margin | -154.8% |
| Last Earnings Update | 31 Dec 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Nabriva Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 22 | 37 | -57 | 45 | 0 |
| 30 Sep 22 | 36 | -47 | 50 | 0 |
| 30 Jun 22 | 35 | -47 | 50 | 0 |
| 31 Mar 22 | 34 | -47 | 52 | 0 |
| 31 Dec 21 | 29 | -49 | 52 | 0 |
| 30 Sep 21 | 22 | -54 | 55 | 0 |
| 30 Jun 21 | 15 | -57 | 53 | 0 |
| 31 Mar 21 | 7 | -60 | 51 | 0 |
| 31 Dec 20 | 5 | -69 | 55 | 0 |
| 30 Sep 20 | 3 | -75 | 55 | 0 |
| 30 Jun 20 | 9 | -80 | 62 | 0 |
| 31 Mar 20 | 9 | -86 | 65 | 0 |
| 31 Dec 19 | 9 | -83 | 62 | 0 |
| 30 Sep 19 | 10 | -91 | 56 | 0 |
| 30 Jun 19 | 3 | -126 | 50 | 0 |
| 31 Mar 19 | 4 | -122 | 45 | 0 |
| 31 Dec 18 | 10 | -115 | 42 | 0 |
| 30 Sep 18 | 10 | -106 | 42 | 0 |
| 30 Jun 18 | 11 | -76 | 39 | 0 |
| 31 Mar 18 | 11 | -72 | 35 | 0 |
| 31 Dec 17 | 5 | -74 | 29 | 0 |
| 30 Sep 17 | 7 | -67 | 23 | 0 |
| 30 Jun 17 | 6 | -59 | 17 | 0 |
| 31 Mar 17 | 7 | -57 | 15 | 0 |
| 31 Dec 16 | 6 | -55 | 14 | 0 |
| 30 Sep 16 | 5 | -67 | 13 | -15 |
| 30 Jun 16 | 5 | -61 | 12 | -8 |
Quality Earnings: NTY is currently unprofitable.
Growing Profit Margin: NTY is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NTY is unprofitable, but has reduced losses over the past 5 years at a rate of 14.9% per year.
Accelerating Growth: Unable to compare NTY's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NTY is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.8%).
Return on Equity
High ROE: NTY has a negative Return on Equity (-1736.56%), as it is currently unprofitable.